Dietary supplements (DS) may influence cancer prognosis. Their use in cancer patients has been described in the United States, but data are largely lacking in Europe and notably in France. The present study's objectives were (1) to assess DS use and its sociodemographic, lifestyle, and dietary correlates in a large sample of French cancer survivors; (2) to evaluate the involvement of physicians in such DS use; and (3) to assess the extent of potentially harmful practices. Data were collected by self-administered web-based questionnaires among participants of the NutriNet-Santé cohort. Data on DS use was available for 1081 cancer survivors. DS users were compared to nonusers with unconditional logistic regressions. DS use was reported by 62 % of women and 29 % of men. Vitamins D, B 6 , C and Mg were the most frequently consumed nutrients. 14 % of cancer survivors initiated DS use after diagnosis. For 35 % of the DS consumed, subjects did not inform their attending physician. DS use was associated with a healthier lifestyle (normal weight, never smoking and better diet) and substantially contributed to nutrient intake. 18 % of DS users had potentially harmful DS use practices, such as the simultaneous use of vitamin E and anticoagulant/antiplatelet agents, the use of b-carotene and smoking or the use of phyto-oestrogens in hormonedependent cancer patients. The present study suggests that DS use is widespread among cancer survivors, a large amount of that use is performed without any medical supervision and a substantial proportion of that use involves potentially harmful practices. Physicians should be encouraged to more routinely discuss DS use with their cancer patients.
Key words: Dietary supplements: Motivations: Correlates: Cancer survivorsWhen disconcerted by their illness and disappointed by traditional medicine, cancer patients can move towards complementary and alternative medicines, including the use of dietary supplements (DS). However, the impact of DS on cancer prognosis, risk of recurrence and risk of second cancer remains unclear (1) . Although the beneficial effects of DS taken during or after cancer treatment are not excluded (2 -4) , several studies have reported adverse effects of some DS on cancer prognoses (1,5 -8) . Presently, it is recommended that phyto-oestrogen DS should be avoided with hormone-dependent cancer patients (6,9) . Similarly, b-carotene DS should not be used with cancer patients or with healthy people who are smokers (10 -12) . In addition, studies haveshown that some vitamin/mineral or herbal DS may interact with anti-cancer or other active treatments (9,13 -15) . This may be particularly problematic if attending physicians have no knowledge of the self-medication practices in their patients. According to a recent review of US studies, 56 -68 % of physicians are not aware of DS use among their cancer patients (16) . In this context, it is essential to assess DS use and its correlates in cancer patients and survivors. Such observational studies have been published...